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Abstract
Current radiographic response criteria for brain tumors have difficulty describing changes surrounding postoperative
resection cavities. Volumetric techniques may offer improved assessment, however usually are time-consuming, subjective
and require expert opinion and specialized magnetic resonance imaging (MRI) sequences. We describe the application of a
novel volumetric software algorithm that is nearly fully automated and uses standard T1 pre- and post-contrast MRI
sequences. T1-weighted pre- and post-contrast images are automatically fused and normalized. The tumor region of
interest is grossly outlined by the user. An atlas of the nasal mucosa is automatically detected and used to normalize levels
of enhancement. The volume of enhancing tumor is then automatically calculated. We tested the ability of our method to
calculate enhancing tumor volume with resection cavity collapse and when the enhancing tumor is obscured by subacute
blood in a resection cavity. To determine variability in results, we compared narrowly-defined tumor regions with tumor
regions that include adjacent meningeal enhancement and also compared different contrast enhancement threshold levels
used for the automatic calculation of enhancing tumor volume. Our method quantified enhancing tumor volume despite
resection cavity collapse. It detected tumor volume increase in the midst of blood products that incorrectly caused
decreased measurements by other techniques. Similar trends in volume changes across scans were seen with inclusion or
exclusion of meningeal enhancement and despite different automated thresholds for tissue enhancement. Our approach
appears to overcome many of the challenges with response assessment of enhancing brain tumors and warrants further
examination and validation.
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Introduction
Assessing radiographic response in patients with brain tumors
can be challenging, especially since they often contain large cysts
or resection cavities and may contain postoperative blood products
that create magnetic resonance imaging (MRI) signal changes
similar to contrast-enhancement. Resection cavities also frequently
have irregular shapes with satellite lesions and small amounts of
postoperative residual rim enhancement which are difficult to
quantify. In addition, over time the cavities can collapse which
dramatically alters the size and configuration of these irregular
enhancing areas.[1,2,3] Thus changes in actual tumor volume are
difficult to describe with traditional measurement techniques.
The most commonly used methods to determine treatment
responses in brain tumors are the Macdonald criteria[4] and the
Response Evaluation Criteria in Solid Tumors (RECIST) criteria
[5]. While the Macdonald criteria incorporate two-dimensional
(2D) measurements with steroid dosing and the patients’
neurological examinations, the more recent RECIST criteria
evaluate tumor response based on measurement of the longest
one-dimensional (1D) diameter. The radiologic assessment for
neuro-oncology (RANO) criteria[6] published recently represent a
modification of the Macdonald criteria that include guidelines for
assessing response in the context of pseudoprogression that can
confound MRI interpretation after combined TMZ chemora-
diotherapy[7]. The RANO criteria also specify the inclusion of
non-enhancing tumor burden for the assessment of response that
has become relevant in the modern era with the widespread use of
anti-angiogenic agents. Despite their ease of use and widespread
application, the Macdonald, RANO and RECIST criteria cannot
accurately describe the amount of residual tumor in surgical
resection cavities (Fig. 1).[2,8] The initial paper by Macdonald
et al. even acknowledges that their criteria should not be applied to
resection cavities, and the RECIST criteria consider all lesions that
are either less than 1 cm or cystic to be unmeasurable, which
would likely exclude rim enhancement around a postoperative
resection cavity.[9] Because of the difficulty applying these existing
methods to postoperative patients, there has been conflicting
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are related to time to progression.[10,11,12] Progression free
survival is nonetheless becoming a more frequently used endpoint
in clinical trials[11,12] and therefore the need is increasing for
improved response assessment techniques.
Other authors have suggested modifications to these criteria
including measuring across cystic areas or resection cavities and
then subtracting a measurement of the cystic areas.[13] A more
complicated scheme used in a major multicenter phase III clinical
trial involves the summation of 2D areas of all tumor nodules with
an estimate of the 2D area of rim enhancement, which is
calculated by multiplying a curvilinear length of the resection
cavity multiplied by the width. Rim enhancement in this trial is
only considered measurable if the width is 5 mm or greater in
width[14]. Despite their increased complexity, these modified
techniques still do not entirely account for small changes that
occur in resection cavities, and alternatively many of these issues
can be overcome with volumetric measurements that can assess
the entire tumor burden.
Volumetric techniques are currently feasible with modern three-
dimensional reconstruction stations and intraoperative navigation
systems, but mostly require experienced operators to manually
outline the tumor volume and then perform the analysis. Since
they depend on the user to outline tumor volume manually, there
can be considerable inta- and inter-user variability in the inclusion
of rim-enhancing resection cavities, blood or other bright lesions in
the resection cavity, and there can be difficulties determining
where the tumor margin ends and normal tissue begins.
Furthermore, these methods can be influenced by differences in
slice acquisition as well as the timing and dose of contrast boluses.
We describe a novel, nearly fully automated software algorithm
that measures enhancing tumor volume and runs on a standard
laptop computer using standard DICOM images of pre- and post-
contrast MRI scans. In this study, we demonstrate that our
method is able to measure tumor volume changes despite resection
cavity collapse, while traditional 1D and 2D techniques are
incorrectly influenced by the overall resection cavity configuration.
We are also able to determine the presence of enhancing tumor
when it is obscured by intrinsically bright T1 objects, such as
subacute hemorrhage in a resection cavity. To demonstrate the
two extremes of inter-user variability, we show similar trends in
our results when the enhancing volume is narrowly defined or
generous and includes the adjacent enhancing meninges. We also
determine that the changes in volume calculations that occur with
different threshold levels for determining tissue enhancement are
minimal.
Materials and Methods
Standard DICOM images of T1-weighted magnetic resonance
imaging (MRI) axial images of the brain before and after contrast
were imported into a standard laptop computer installed with our
novel volumetric assessment software. The computer program
automatically fuse pre and post contrast images (Fig. 2A). As
depicted in Fig. 2B, the user grossly outlined the tumor region of
interest in the T1-weighted axial post-contrast scan and arbitrarily
outlined a region of normal brain parenchyma, not including
vessels, ventricles, sulci, or other cerebrospinal fluid (CSF) spaces.
The computer program automatically analyzed the outlined
normal brain parenchyma to compensate for variability in scan
brightness and lack of standardized pixel values in MRI scans. For
studies involving meningeal enhancement, the operator intention-
ally grossly outlined the tumor region with and without including
the adjacent meninges.
The program automatically detected the nasal mucosa based on
an anatomic atlas (Fig. 2C). It automatically calculated enhancing
tumor volume from within the grossly defined region of interest, as
depicted in Fig. 2D, using a rigorous computational algorithm that
can be briefly described as follows. Within the outlined normal
region, our program calculated the subtracted pixel values
between pre- and post-contrast scans. The mode of these
subtracted values was determined and used as a correction factor
for all subsequent data analyses. The pixel values within the tumor
region and the nasal mucosa region were subtracted between pre-
and post-contrast scans, and then this calculated correction factor
was also subtracted, to generate corrected tumor values and
Figure 1. Traditional Non-Volumetric Measurements do not Adequately Describe Residual Enhancement in Surgical Resection
Cavities. A) This schematic resection cavity has residual rim enhancement in gray. RECIST criteria measurement ‘A’ or ‘a’ or ‘b’ or Macdonald criteria
measurement ‘A*B’ or ‘a*b’ would not adequately describe residual tumor volume and additional tumor growth around the rim or collapse of the
resection cavity may be over- or under-interpreted. B) Differences in axial slice acquisition also impact measurements made by traditional criteria
more than volumentric measurements. One scan could obtain axial slice ‘c’ with enhancing tumor measurement ‘x’ but a subsequent scan in the
same patient could obtain axial slice ‘d’, causing an incorrect assessment of tumor response.
doi:10.1371/journal.pone.0016031.g001
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mucosa values derived from the nasal mucosa atlas were excluded
to avoid error, and then the threshold for enhancement was set to
be 25% of this remaining maximum value. This number was
subsequently used as the threshold above which tissue was defined
to be enhancing. For the studies involving different threshold
levels, 25%, and 40% were used as the different experimental
threshold values. The number of pixels in the tumor region of
interest above the enhancement cut-off was calculated to
determine the enhancing tumor volume. These calculations are
all performed automatically once the regions of interest are grossly
outlined by the user.
Results
Detection of Enhancing Tumor with Resection Cavity
Collapse
Traditional methods struggle to determine changes in enhanc-
ing tumor when the configuration of the resection cavity changes.
Fig. 3A demonstrates a single axial slice from an MRI of a
postoperative resection cavity with rim enhancement. Using the
RECIST criteria, measurement would be 4.3 cm (‘‘A’’). Similarly,
using the Macdonald criteria, the measurement would be 4.3 cm *
3.2 cm=13.8 cm
2 (‘‘A’’ * ‘‘B’’). Volumetric measurement of the
area around the resection cavity with our method identifies
1.26 cm
3 of enhancing tumor, which intuitively appears to
quantify the amount of residual tumor more accurately. Moreover,
it allows more accurate comparisons with follow-up scans. For
example, Fig. 3B demonstrates collapse of this resection cavity,
and both RECIST measurement (‘‘a’’ =3.7 cm) and the
Macdonald measurement (‘‘a * b,’’ =3.7 * 1.7=6.29 cm
2) are
smaller due to this cavity collapse, which appears counter-intuitive.
Our volumetric method, however, identifies 5.58 cm
3 of enhanc-
ing tumor indicating that the tumor burden had actually
increased. However, Macdonald and RECIST measurements
which included changes in the resection cavity configuration,
assess overall tumor enhancement as decreasing despite an
increase in rim enhancement. Of note, the patient continued to
progress over the next four months with an increase in
enhancement volume to 9.82 cm
3,Tumor progression was also
confirmed with a subsequent biopsy in this case.
Subacute Blood
By comparing between pre- and post-contrast scans and using
nasal mucosa enhancement as a reference, our volumetric
program is able to subtract intrinsically bright T1 signal so that
elements that are bright on both scans (i.e. blood products in a
resection cavity) can be differentiated from enhancing tumor that
is only bright in the post-contrast scan. Figs. 4A and 4B show an
example where the intrinsically bright T1 signal of subacute blood
Figure 2. Automated Assessment of Enhancing Tumor Volume. A) T1-weighted post-contrast axial images are automatically fused with the
pre-contrast sequences. B) The tumor region of interest (blue area) and nearby normal brain (purple area) are outlined roughly by hand. C) The
enhancing nasal mucosa region is automatically detected with a built-in anatomic atlas (red area) and serves as a threshold for enhancement. D)
Tissue that is present on the post-contrast images but not the pre-contrast that is above the enhancement threshold appears in yellow. This includes
enhancing tissue such as vasculature, tumor, and superficial structures. Enhancing tumor volume is defined as the green area within the manually-
defined blue tumor region of interest.
doi:10.1371/journal.pone.0016031.g002
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on the post-contrast scan. Our volumetric method was able to
successfully detect 3.06 cc of residual tumor enhancement despite
the presence of intrinsically high T1 signal, as shown in Fig. 4C.
RECIST measurement was 3.6 cm and Macdonald measurement
was 8.64 cm
2. The enhancing tumor volume calculated by our
methods corresponds well to the true residual enhancing tumor, as
confirmed on a subsequent MRI performed 2.5 months later in
this patient after the subacute blood had resolved to reveal a
residual enhancing tumor of 4.48 cc (Fig. 4D).
Figure 3. Detection of Enhancing Tumor Volume Despite Resection Cavity Collapse. A) T1-weighted post-contrast axial image showing a
resection cavity with rim enhancement. RECIST measurement would be A and Macdonald measurement would be ‘‘A * B’’. B) T1-weighted post-
contrast axial image showing the same patient 3 months postoperatively who had collapse of his resection cavity. RECIST measurement would be ‘‘a’’
and Macdonald measurement would be ‘‘a * b’’, both of which would be smaller than the measurements from the initial scan above, but this change
would be describing only the resection cavity configuration and not the underlying tumor burden.
doi:10.1371/journal.pone.0016031.g003
Figure 4. Detection of Enhancement that is Obscured by Blood Products. A) Uncontrasted T1-weighted axial image showing resection
cavity blood products (bright on T1). B) T1-weighted post-contrast axial image showing the difficulty in determining residual enhancing tumor. C)
Our volumetric analysis is able to detect the obscured enhancing tumor tissue (shown in green). D) T1-weighted post-contrast axial image at 2.5
months later after the blood has resolved verifying the underlying enhancing tumor volume.
doi:10.1371/journal.pone.0016031.g004
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Most volumetric techniques are hampered by the need for
expert opinion to distinguish true enhancing tumor from adjacent
normal brain and postoperative changes such as enhancing
meningeal scar. Similarly, a potential source of variability in the
use of any volumetric method is the amount of adjacent
enhancement (including meningeal scarring, blood vessels, choroid
plexus, etc.) the user includes when grossly outlining the region of
interest. As Figs. 5A and 5B demonstrate, when a generous tumor
region of interest including surrounding meningeal enhancement
is outlined, the total calculated enhancing volume is greater than
when a narrowly defined tumor region is outlined. However, a
benefit of our method is that sequential scans are fused together by
the program so that the tumor region of interest grossly outlined
on the initial patient scan is directly transferred to subsequent
scans for that patient. Enhancing volume calculations of serial
scans both with and without the adjacent meningeal enhancement
were performed and Fig. 5C shows that there is little difference in
the change between scans regardless of technique to define the
tumor region of interest.
Variability in Enhancement Threshold
Our semi-automated volumetric method uses a pre-defined
percent threshold of the enhancing nasal mucosa in each patient
scan for identification of enhancing tissue within the tumor region
of interest. Increasing the percent threshold will decrease the
calculated enhancing volume, while decreasing the threshold
will increase the calculated volume, as graphically depicted in
Figs. 6A–B. Fig. 6C shows the results of enhancing volume analysis
with different thresholds in serial scans of patients. Comparison
between a 40% threshold with a 25% threshold yielded a high
correlation (r=0.96; P,0.0001). Therefore, when the defined
threshold level is maintained consistently through serial scans, the
results are highly correlated regardless of the specific threshold
level.
Discussion
Our volumetric method demonstrates promise in the response
assessment of enhancing brain tumors. It can account for
enhancing tumor despite expected postoperative collapse of the
resection cavity and is able to detect enhancing tumor in the midst
of intrinsically bright T1 signal, such as in postoperative resection
cavities with a small amount of hemorrhage. These situations
frequently occur in brain tumor patients after surgical resection
and have been difficult to describe with traditional response
assessment methods.
Technical differences, such as contrast dose and gantry angle,
for serial MRI scans can lead to the false appearance of changes in
the amount of tumor enhancement. Our method overcomes these
problems by using image fusion to eliminate differences from slice
acquisition, and it uses a cutoff for enhancement that is calculated
for each scan to minimize the importance of variations in contrast
bolus and enhancing signal intensity between different MRI scans.
Since our program runs on a laptop computer and analyzes
DICOM data directly from standard T1 pre- and post-contrasted
sequences that patients typically bring to clinic on a CD,
Figure 5. Effect of Inter-observer Differences in Definition of Tumor Volume. A) Axial T1-weighted post-contrast image showing a limited
user-defined tumor region of interest. B) The same axial image now showing a large user-defined tumor region of interest that encompasses the
meningeal enhancement. C) While including the meninges increases the enhancing volume, similar trends in changes of volume over time are seen.
doi:10.1371/journal.pone.0016031.g005
Volumetric MRI Response for Brain Tumors
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e16031widespread adoption of our method would be easier than other
techniques that require specialized MRI sequences or computer
systems. For example, others have developed a parametric
response map with perfusion MRI data to predict overall
survival.[15] A significant amount of work has also been devoted
to adapting diffusion MRI imaging for the assessment of tumor
response[16,17,18,19]. These and similar techniques are hindered
in their acceptance since these specialized sequences may not be
routinely obtained.
It is expected that the increased automation of our approach
should improve the reproducibility of calculated tumor volumes,
but this still needs to be studied and validated prospectively. In
support of this assumption, Schwartz et al. found that in CT
assessment of solid tumors, techniques that employed increased
automation obtained results that were more accurate and
consistent than manual methods.[20] Other studies using
automated CT volumetric methods in pulmonary tumors suggest
superiority when compared to manual RECIST measurements.
[21,22] For gliomas, Sorensen et al. found that a computer-assisted
perimeter method of volume calculation produced less inter- and
intra-user variability than a manual volumetric calculation that
used diameter measurements.[13] In addition to increased auto-
mation, our method specifically detects only enhancing tissue.
Other semi-automated tumor assessment methods, including
automatic segmentation methods that use fuzzy clustering and
interactive watershed algorithms, do not take into account tumor
enhancement specifically.[23,24,25]
Our results suggest that there would be limited variability in
results with different users of our method, since similar trends in
volume change were seen with both inclusion or exclusion of the
adjacent meningeal enhancement. Future studies will be directed
at examination of inter-user variability with our method.
Generally, volumetric measurements are expected to have less
measurement variability than 1D or 2D methods, thereby
improving repeatability and possibly decreasing the sample size
needed in studies to ascertain treatment effects.[2] By accounting
for the entire tumor burden, it is expected that volumetric
measurement should allow for the detection of tumor response or
progression sooner than Macdonald and RECIST criteria. This
should substantially reduce intra-observer variability. It is likely
that these two different user techniques will not substantially
impact response assessment as tumor response criteria are based
on percent changes between scans and not absolute measure-
ments. In support of these assumptions, Dempsey et al. found that
volumetric measurements, and not 1D or 2D methods, were
predictive of survival.[26] Numerous other studies have been
performed comparing 1D, 2D and volumetric measurements, with
many showing good agreement between all three methods in
classifying response and predicting survival.[27,28] Comparisons
made by Warren et al. in pediatric brain tumor patients found
Figure 6. Effect of Different Enhancement Thresholds. A) Axial T1-weighted post-contrast image after volumetric analysis has been performed
which shows in green the detected enhancing tumor volume using a 25% threshold level. B) Detected enhancing tumor volume using a 40%
threshold level. C) While increasing the threshold decreases the calculated tumor volume, the volumes across different threshold levels are highly
correlated.
doi:10.1371/journal.pone.0016031.g006
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compared with manual volumetric measurements, and although
all three techniques had high concordance in detecting partial
responses, this was not true for minor responses or tumor
progression, and there was significant variability across measure-
ments in estimating time to disease progression.[29] CT-based
volumetric assessment of solid tumors has shown varying degrees
of correlation with 1D and 2D methods.[30,31] Formal compar-
ison of our method with traditional assessment techniques is
planned.
An important difficulty with measuring enhancing brain tumors
on MRI is that there is no quantitative cutoff for tissue
enhancement on MRI. There have been a few previous descrip-
tions of a formulaic determination of an enhancement threshold
based on the initial peak enhancing signal increase, but this has not
been widely accepted.[32,33] Many previous methods have simply
utilized expert opinion to select the enhancing tissue according to
their best judgment, however this technique invites significant
subjective error, as different experts may have different opinions.
Our method attempts to address this inherent limitation of MRI
scans and still minimize subjectivity by increasing computer
automation and calculating an internal threshold for tissue
enhancement. The 25% threshold level we have adopted is based
on expert radiologist opinion determining which level best
corresponds to their judgement of enhancing tissue. Use of a
standard threshold has precedence in other fields. With positron
emission tomography (PET) scans, the detected intensity tapers off
over distance from the source, so it is difficult to delineate precisely
where the intensity is no longer apparent. A number of different
methods have been attempted to estimate the tumor region of
interest, and a set 40% threshold of either the source-to-
background (S/B) ratio or of the maximum standardized uptake
value (SUV) are commonly advocated techniques.[34,35] Our
results show a high degree of correlation between different
threshold levels however, which supports the validity of this
technique but also suggests that the specific threshold level chosen
is not critical as long as the same level is used consistently.
Despite these advantages, our novel volumetric approach is
based on the measurement of tissue enhancement, and therefore
will not accurately quantify tumor burden if there is a significant
amount of non-enhancing tumor. Even in enhancing tumors, there
has recently been increasing use of anti-angiogenic agents such as
bevacizumab that normalize vasculature and decrease enhance-
ment leading to potential over-interpretations.[36,37,38] Other
authors have noted that since enhancement can change due to
radiation necrosis, pseudo-progression, steroid treatment, or
pseudo-response, enhancement does not always reflect changes
in the underlying tumor.[8] The RANO criteria were drafted to
attempt to address these limitations[6]. Difficulty visualizing non-
enhancing tumor burden is a problem for most proposed methods
of assessing tumor response, and some authors have advocated
that response criteria in these situations may have to be altered to
include both radiologic changes and measurements of circulating
biomarkers.[39] Unfortunately, these limitations are equally
applicable to the Macdonald or RECIST criteria. The initial
paper by Macdonald et al. even acknowledges that their criteria
should not be applied to non-enhancing tumor.[4] As such, our
method still represents an advance over current assessment
techniques, and modification of our program to incorporate T2/
FLAIR MRI sequences is currently being attempted to address
this limitation.
Our novel volumetric method appears promising in the
assessment of radiographic response for the majority of enhancing
gliomas. Future studies will be needed to validate this method
against other outcome assessment techniques, since subtle changes
in tumor volume may not have clinical relevance. However our
method offers the potential to characterize small enhancement
changes that can occur over time due to a variety of factors
including pseudoprogression, pseudoresponse, radiation necrosis,
steroid treatment, and disease recurrence, as many of these
imaging changes still lack detailed descriptions.[7,40,41,42]
Determination of the magnitude and time course of these different
changes may lead to greater ability to distinguish between actual
disease recurrence and other causes of enhancing volume change.
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